News
-
-
COMMUNIQUÉ DE PRESSE
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025
Pentixapharm presents first-in-human data on Lu177-PentixaTher for Muscle-Invasive Bladder Cancer at ASCO-GU 2025, showing potential for bladder preservation and targeted treatment -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million
Pentixapharm Holding AG reports a 2024 financial year loss of EUR 14 million, including risk provisions for Myelo. Find more details in the upcoming annual report -
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
Pentixapharm receives EUR 6.77 million for intangible assets formerly developed by Glycotope from undisclosed Asian pharma and biotech companies, eliminating remaining earn-out obligations -
-
